Sepracor president told analysts that Lunesta share nearing 40%

Share this article:
Sepracor president William O'Shea told analysts and investors that Lunesta's share of the sleep-aid market is nearing 40%, thanks to the company's aggressive direct-to-patient promotional efforts. The firm will now initiate “Phase Two” of its Lunesta promotion by increasing sales capacity and rolling out its expanded clinical database for the drug, he said in the company's first-half earnings report. The firm reported six-month Lunesta revenues of $277 million.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.